← 產業報告目錄
Anticoagulant Reversal Drugs Market, By Product Type (Idarucizumab, Protamine, Prothrombin Complex Concentrates, Phytonadione, Andexanet Alfa, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
出版商 Coherent Market Insights出版日期 2026-07-06頁數 258報告編號 CMR-9161bfd82b
授權報價
| Single User Price | $4,500 USD |
| Site License Price | $7,000 USD |
| Enterprisewide Price (Global Site License) | $10,000 USD |
報告摘要
Anticoagulation drug therapy is prescribed in patients who are suffering from a venous atrial fibrillation (AF), thromboembolism, mechanical valve replacement, and other coagulation disorders such as antiphospholipid antibody syndrome and Factor V Leiden. In some instances, such as unexpected surgery or anticoagulant overdose, anticoagulant reversal drugs are necessary to reverse the impact of anticoagulation. Increased frequency of cerebral & gastrointestinal haemorrhage and new technology add-on status (NTAP) granted to certain medicines, which focuses on the development of specialised drugs for anticoagulation reversal. Fresh frozen plasma is frequently used to counteract the effects of warfarin, although complete reversal takes six to 24 hours. Prothrombin complex concentrates (PCCs) can be utilised in more urgent situations since they give full anticoagulation reversal in 15-20 minutes.
Several reversal medicines have been developed for patients using newer oral anticoagulants. However, it should be emphasised that these newer anticoagulants have short half-lives (5-17 hours), and reversal is rarely indicated. Reversal medicines have a risk of life-threatening thrombosis and should be used only under the supervision of a professional with experience in their usage and/or in a patient who is at urgent danger of death from bleeding. In most cases, a single dosage is administered. However, dosing may be repeated in exceptional cases when the oral anticoagulant remains in the blood for a prolonged period of time, such as severe renal failure.
Market Dynamics
Increasing spending in research and development is anticipated to propel the anticoagulant reversal drugs market growth during the forecast period. For instance, in December 2020, Octa Pharma USA released the findings of clinical study conducted to assess the safety and efficacy of fibryga, a Human Fibrinogen Lyophilized Powder for Reconstitution recommended for intravenous use in the treatment of congenital and acquired bleeding disorders, in the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.
Key features of the study
• This report provides an in-depth analysis of the global anticoagulant reversal drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global anticoagulant reversal drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Portola Pharmaceuticals, Boehringer Ingelheim, CSL Behring, Bausch Health Companies Inc., Octapharma AG, Dr. Reddy's Laboratories, AMAG Pharmaceuticals, Inc., Pfizer, Inc., SGPharma Pvt. Ltd., Alps Pharmaceutical Ind. Co., Ltd., Fresenius Kabi AG, Mundipharma International Limited, and Hisamitsu Pharmaceutical Co., Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global anticoagulant reversal drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global anticoagulant reversal drugs market
Market Segmentation
• By Product Type Insights (Revenue, USD Mn, 2021 - 2033)
o Idarucizumab
o Protamine
o Prothrombin Complex Concentrates
o Phytonadione
o Andexanet Alfa
o Others
• By Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
o Hospital Pharmacy
o Retail Pharmacy
o Online Pharmacy
• By Region Insights (Revenue, USD Mn, 2021 - 2033)
o North America
U.S.
Canada
o Latin America
Brazil
Argentina
Mexico
Rest of Latin America
o Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC
Israel
Rest of Middle East
o Africa
North Africa
Central Africa
South Africa
• Key Players
o Portola Pharmaceuticals
o Boehringer Ingelheim
o CSL Behring
o Bausch Health Companies Inc.
o Octapharma AG
o Reddy's Laboratories
o AMAG Pharmaceuticals, Inc.
o Pfizer, Inc.
o SGPharma Pvt. Ltd.
o Alps Pharmaceutical Ind. Co., Ltd.
o Fresenius Kabi AG
o Mundipharma International Limited
o Hisamitsu Pharmaceutical Co., Inc.
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Product Type
Market Snapshot, By Distribution Channel
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Opportunity
o Impact Analysis
o Pipeline Analysis
o Regulatory Scenario
o Market Trends
o Key Developments
o Epidemiology
o PEST Analysis
o Brand Analysis
4. Global Anticoagulant Reversal Drugs Market, By Product Type, 2021 – 2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Idarucizumab
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Protamine
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Prothrombin Complex Concentrates
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Phytonadione
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Andexanet Alfa
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
5. Global Anticoagulant Reversal Drugs, By Distribution Channel, 2021 – 2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Hospital Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Retail Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Online Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
6. Global Anticoagulant Reversal Drugs Market, By Region, 2021 – 2033, (USD Mn)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2022–2033
Regional Trends
o North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021 – 2033, (USD Mn)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021 – 2033, (USD Mn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021 – 2033, (USD Mn)
o U.K.
o Germany
o France
o Italy
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021 – 2033, (USD Mn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Types, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021 – 2033, (USD Mn)
o GCC
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Countries/Region, 2021 – 2033, (USD Mn)
o North Africa
o Central Africa
o South Africa
7. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
Portola Pharmaceuticals
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Boehringer Ingelheim
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
CSL Behring
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Bausch Health Companies Inc.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Octapharma AG
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Reddy's Laboratories
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
AMAG Pharmaceuticals, Inc.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Pfizer, Inc.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
SGPharma Pvt. Ltd.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Alps Pharmaceutical Ind. Co., Ltd.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Fresenius Kabi AG
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Mundipharma International Limited
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Hisamitsu Pharmaceutical Co., Inc.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
o Analyst Views
8. Section
o Research Methodology
o About us
圖表清單 List of Tables & Figures
NA
NA
提及公司
o Portola Pharmaceuticalso Boehringer Ingelheimo CSL Behringo Bausch Health Companies Inc.o Octapharma AGo Reddy's Laboratorieso AMAG PharmaceuticalsInc.o PfizerInc.o SGPharma Pvt. Ltd.o Alps Pharmaceutical Ind. Co.Ltd.o Fresenius Kabi AGo Mundipharma International Limitedo Hisamitsu Pharmaceutical Co.Inc.
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們